Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 1882

The Rebellionaire Road Rally has made its way down to Austin, TX. This time we’re joined by Farzad (@farzyness) to test out Tesla FSD v12 on the streets of the greater Austin area. This is part 2 of the journey with Farzad joining in the car adding helpful commentary.

#Tesla #rebellionaire.

Rebellionaires check out www.Rebellionaire.com.
Rebellionaire is a brand of Halter Ferguson Financial. www.hffinancial.com/disclaimer.

As of March 7th, 2024, clients and employees of our firm Halter Ferguson Financial own Tesla stock and/or options and thereby stand to materially benefit from a rise in the share price. Past performance is no assurance of future results. Halter Ferguson Financial, Inc. (“Halter Ferguson Financial”) is a registered investment adviser with its principal place of business in the State of Indiana. A complete list of all recommendations will be provided if requested for the preceding period of not less than one year. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. Opinions expressed are those of Halter Ferguson Financial, Inc. and are subject to change, not guaranteed and should not be considered recommendations to buy or sell any security.

Continue reading “Tesla FSD v12 drives like a teenager!” | >

Thrombolytic therapy administered longer after the onset of ischemic stroke than current recommendations did not demonstrate improved clinical outcomes as compared to placebo, according to a recent trial published in the New England Journal of Medicine.

Minjee Kim, MD, associate professor in the Ken and Ruth Davee Department of Neurology’s Division of Neurocritical Care, was a co-author of the study.

Ischemic stroke occurs when a blood vessel supplying blood to the brain is blocked or reduced, and accounts for nearly 90% of all strokes, according to statistics from the American Stroke Association.

Read more | >

The Melanoma Antigen Gene (MAGE) family consists of more than 40 proteins in humans, most of which are only present in the testes under healthy conditions. However, in many cancers, these proteins are found in high levels in tissues where they are not usually expressed and are believed to play a role in promoting cancer progression. Researchers from the Bhogaraju group at the European Molecular Biology Laboratory (EMBL) Grenoble have gained new insights into how these proteins bind their targets. The findings could potentially aid in the development of drugs against chemotherapy-or radiotherapy-resistant cancers.

The findings are published in The EMBO Journal, in an article titled, “Structural basis for RAD18 regulation by MAGEA4 and its implications for RING ubiquitin ligase binding by MAGE family proteins.”

“MAGEA4 is a cancer-testis antigen primarily expressed in the testes but aberrantly overexpressed in several cancers,” the researchers wrote. “MAGEA4 interacts with the RING ubiquitin ligase RAD18 and activates translesion DNA synthesis (TLS), potentially favoring tumor evolution. Here, we employed NMR and AlphaFold2 (AF) to elucidate the interaction mode between RAD18 and MAGEA4, and reveal that the RAD6-binding domain (R6BD) of RAD18 occupies a groove in the C-terminal winged-helix subdomain of MAGEA4.”

Read more | >

Using cellulose from trees and a synthetic polymer, MIT researchers have created a material that “is stronger and tougher than some types of bone, and harder than typical aluminum alloys,” the university announced.

The researchers hope their compound could lead to better, more sustainable plastics in the future. Currently, the material shrinks while drying, making printing anything large out of it difficult.

“If you could avoid shrinkage, you could keep scaling up, maybe to the meter scale,” said MIT’s Abhinav Rao. “Then, if we were to dream big, we could replace a significant fraction of plastics with cellulose composites.”

Read more | >

Without a more comprehensive set of big data, AI algorithms are more likely to generate an inaccurate or incomplete data model. Insufficient data leads to a model that is not capable of predicting outcomes with the level of accuracy that’s needed in the real world.

Anyone with experience in the art market also knows that markets can fluctuate without any indication as to why. AI will not have the answer. Tech entrepreneur Boris Pevzner, founder of AI-powered data platform Live Art, asserts that while AI is a tool that can be used as an indicator, it is not something that can predict any real-world auction prices.

Although AI is becoming increasingly prevalent in the art business, it does not have to be seen as a threat. Many people view AI as a dangerous tool, but AI does not need to be perceived in this way. Instead of a replacement for human expertise, we should see it as a tool of advancement to be used alongside humans to improve the quality of their work.

Read more | >

The eyes have been called the window to the brain. It turns out they also serve as an immunological barrier that protects the organ from pathogens and even tumors, Yale researchers have found.

In a new study, researchers showed that vaccines injected into the eyes of mice can help disable the herpes virus, a major cause of brain encephalitis. To their surprise, the vaccine activates an immune response through lymphatic vessels along the optic nerve.

Read more | >

Transplanting Whole Human Eyes To Restore Vision In Patients Who Are Blind Or Visually Impaired — Dr. Calvin Roberts, MD — Program Manager, Transplantation of Human Eye Allografts (THEA), Advanced Research Projects Agency for Health (ARPA-H)

Dr. Calvin Roberts, M.D. is Program Manager at the Advanced Research Projects Agency for Health (ARPA-H) where manages for the Transplantation of Human Eye Allografts (THEA — https://arpa-h.gov/research-and-fundi…) program, which aims to transplant whole human eyes to restore vision in patients who are blind or visually impaired by reconnecting the nerves, muscles and blood vessels of whole donor eyes to the brain.

Dr. Roberts joined ARPA-H in September 2023 from Lighthouse Guild International, where is the president and chief executive officer. Lighthouse Guild is a not-for-profit organization that provides programs and services to people who are blind or visually impaired.

Continue reading “Dr. Calvin Roberts, M.D. — Program Manager, Transplantation of Human Eye Allografts (THEA), ARPA-H” | >